Lexeo Therapeutics, Inc. · NASDAQ:LXEO

Lexeo Therapeutics — Technical Presentation (November 2026)

14 slides from Lexeo Therapeutics's technical presentation, November 2026

  1. Slide 1: Mechanistic Insights and Gene Therapy Rescue in a Porcine Model of TNNI3 Cardiomyopathy

    Mechanistic Insights and Gene Therapy Rescue in a Porcine Model of TNNI3 Cardiomyopathy Elizabeth Silver, MD Adler Lab, UC San Diego Internal Medicine Resident, Massachusetts General Hospital Melvin L. Marcus Early Career Investigator Award American Heart Association Scientific Sessions 2026

  2. Slide 2: Mutations in cardiac troponin I (TNNI3) can cause severe cardiomyopathy with impaired relaxation

    Background Mutations in cardiac troponin I (TNNI3) can cause severe cardiomyopathy with impaired relaxation Familial TNNI3 A157V Cardiomyopathy: • Severe restrictive phenotype with marked LA (Shave 2010) enlargement Cardiac troponin I regulates thin-filament inhibition • Multiple family members requ

  3. Slide 3: TNNI3 A158V mice exhibit impaired relaxation without overt cardiomyopathy

    Background TNNI3 A158V mice exhibit impaired relaxation without overt cardiomyopathy Preserved cardiac structure Impaired relaxation: and survival: Minimum dPdT Invasive hemodynamics Myofibril Mechanics 0 M +/+ • 100% survival at 1 year * * *** **** M +/- Min dP/dT * • No cardiac hypertrophy -5000 M

  4. Slide 4: Can a large-animal model better recapitulate the severe human phenotype?

    Study Design Can a large-animal model better recapitulate the severe human phenotype? Model Generation Experimental Strategy sgRNA PHENOTYPE (cccagcagugccugcaucau) • Survival • Histology Ex 6 Ex 7 Ex 8 • Echocardiography D A M M Q A L L G A R MECHANISM gat gcc atg atg cag gca ctg ctg ggg gcc agg • M

  5. Slide 5: A158V pigs develop severe early-onset cardiomyopathy

    Results: Phenotype A158V pigs develop severe early-onset cardiomyopathy 100% mortality by age 60 days Marked concentric hypertrophy Echocardiographic hypertrophy and diastolic dysfunction WT A158V Histologic fibrosis and inflammation

  6. Slide 6: A158V pigs exhibit impaired relaxation and altered TnI regulation

    Results: Mechanism A158V pigs exhibit impaired relaxation and altered TnI regulation Preserved force generation with impaired relaxation Reduced TnI Ser23/24 phosphorylation WT A158V Hspd1 TnI P-TnI Ser23/24 p = 0.046

  7. Slide 7: A158V pig hearts exhibit inflammatory transcriptional remodeling

    Results: Mechanism A158V pig hearts exhibit inflammatory transcriptional remodeling Distinct transcriptional profiles Inflammatory pathway activation

  8. Slide 8: Single-nucleus sequencing reveals extensive cellular and cardiomyocyte remodeling

    Results: Mechanism Single-nucleus sequencing reveals extensive cellular and cardiomyocyte remodeling Altered cellular composition Cardiomyocyte stress and altered contractile gene programs CM4 CM4 WT A158V Myeloid Lymphoid CM2 CM2 CM1 CM3 CM1 CM3 Endothelial Cardiomyocyte Mural CM4 Fibroblast UMAP U

  9. Slide 9: Interferon-stimulated gene (ISG) expression is enriched in non-cardiomyocyte populations

    Results: Mechanism Interferon-stimulated gene (ISG) expression is enriched in non-cardiomyocyte populations Increased ISG scores in A158V hearts ISG activation in non-cardiomyocyte populations p < 0.0001

  10. Slide 10: TNNI3 A158V causes conserved myofibril relaxation defects but distinct transcriptional phenotypes across species

    Discussion: Pig-Mouse Model Comparison TNNI3 A158V causes conserved myofibril relaxation defects but distinct transcriptional phenotypes across species A158V Mouse A158V Pig Phenotype Normal survival and echos Early mortality, hypertrophy, fibrosis Impaired relaxation on invasive hemodynamics Myofib

  11. Slide 11: MyoAAV-TNNI3 gene replacement prolongs survival in A158V pigs

    Results: Therapy MyoAAV-TNNI3 gene replacement prolongs survival in A158V pigs Cardiac-directed gene replacement Prolonged survival Capsid: MyoAAV Treatment design Mean survival: 55 → 90 days

  12. Slide 12: MyoAAV-TNNI3 gene replacement improves cardiac remodeling and myofibril relaxation

    Results: Therapy MyoAAV-TNNI3 gene replacement improves cardiac remodeling and myofibril relaxation Reduced LV hypertrophy and improved filling Gene replacement rescues myofibril relaxation; mavacamten does not Untreated Treated

  13. Slide 13: Conclusions

    Conclusion Conclusions DISEASE MODEL MECHANISM RESCUE The same sarcomeric Mouse and pig hearts Gene replacement relaxation defect is associated exhibit distinct improves relaxation and with dramatically different transcriptional responses, survival, supporting gene disease phenotypes across with pro

  14. Slide 14: References

    References 1. Cheng Y, Regnier M. Cardiac troponin structure-function and the influence of hypertrophic cardiomyopathy associated mutations on modulation of contractility. Arch Biochem Biophys. 2016;601:11-21. doi:10.1016/j.abb.2016.02.004 2. Yamada Y, Namba K, Fujii T. Cardiac muscle thin filament

Lexeo Therapeutics — Technical Presentation (November 2026) on 6ix